Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Nonpartisan Lawmaker League OKs Dementia Bill, Eyes Enactment in Current Diet
May 11, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Label Revisions Ordered for 32 Hypertension Meds to Caution against Fetal Risks
May 10, 2023
- LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
- MHLW Panel OKs 197 More Health Damage Claims for COVID Vaccines
May 10, 2023
- Chuikyo to Go Back Offline from May, but Online Viewing Still Available
May 9, 2023
- FY2023 COVID Booster Program Begins for Elderly, Health Workers
May 9, 2023
- Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
- PMDA, NHO Ink Database Deal, Data on 9 Million-Plus People to Be Available
May 8, 2023
- MHLW to Decide on Policy for Real-Time Supply Info System within FY2023: Official
May 8, 2023
- Japan Ends Priority Review for COVID Products with Severity Downgrade
May 8, 2023
- Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- LDP League Calls for Generic Market Entry Rules to Ensure Supply: Draft Proposal
April 28, 2023
- Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
- As Japan Mulls Pushing Back Fee Revisions, Chuikyo Reps Fret Impact on Drug Price Updates
April 27, 2023
- Shionogi CEO Presses Govt for G7 Debate on Pull Incentives for Antibiotics
April 27, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
April 27, 2023
- Ultomiris Clears Japan Panel Review for NMOSD Approval
April 27, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…